Advanced Wound Care Global, our vehicle for bringing advanced wound care to areas of the world where the need and opportunity are greatest, was recently invited by Asian Hospital & Healthcare Management to share our thoughts on the potential for advanced wound care in Asia. Here is a brief excerpt from the intro: Asia has … Read More
Yesterday (29 Jul 2021), Bioventus and Misonix jointly announced an M&A. This deal is particularly significant in the advanced wound care (AWC) space for three reasons: The combined entity will be a “new” relatively large advanced wound care player (though similar to Misonix pre-deal, not necessarily with AWC as its sole focus). This is also … Read More
Today (6 Jan 2021), Henry Schein, a top global medical, dental, and veterinary solutions provider / distributor with a global presence, announced its acquisition of a majority ownership position in Prism Medical Products, one of the top US DME (durable medical equipment) providers focused on shipping products to the home. Recent forays into this space … Read More
Today (14 May 2020), Net Health, a leading specialty health software firm with particularly successful market penetration in US wound clinics, announced the acquisition of Tissue Analytics. The entire TA team will remain and join the Net Health organization. This development is significant to the advanced wound care and adjacent industries for many reasons. By … Read More
![Followup Q&A to April 2020 Business of US Wound Care for Executives eLive Event [Video]](http://cdn-5d8acb16f911c90950a62254.closte.com/wp-content/uploads/2020/04/Diligence-Wound-Care-Global-Business-of-US-Wound-Care-Followup-QA-545x394-1.png "Followup Q&A to April 2020 Business of US Wound Care for Executives eLive Event [Video]")
For those of you who joined our recent (April 2020) eLive interactive events on The Business of US Wound Care for Executives (with Healiant Wound Training Solutions), have no fear. Firstly, we have scheduled our upcoming events for May 28th and June 3rd, 2020 respectively. The May 28th session will be more strategic in nature–tailored … Read More
Advanced wound care’s position in the evolving COVID-19 landscape Global economies have been slammed by COVID-19 in the first part of the year. Some biomed sectors, such as PPE, respiratory, and telemed solutions, have seen unprecedented demand for increased production/availability and new innovation alike. On the other hand, orthopedics, plastics, and other service lines with … Read More
Despite the overwhelming majority of R&D, regulatory, sales, marketing, and corporate finance focus in the advanced wound care (AWC) sector being on physical advanced wound care products, many of the greatest opportunities to drive outcomes–and profitability–exist in the realm of wound care service delivery. This concept was further developed by senior management from several of … Read More
The European Wound Management Association (EWMA) conference in Gothenburg, Sweden earlier this month was a great success. We witnessed several important advanced wound care innovations and announcements: From new approaches for addressing nonviable tissue and infection, to CTPs (cellular and tissue-based products) which are financially viable in non-US markets, to sensors and other digital health … Read More
![Consolidation, M&A Integrations as a Competitive Advantage, and Other Advanced Wound Care Industry Insights from 1H 2019 and SAWC Spring [Video]](http://cdn-5d8acb16f911c90950a62254.closte.com/wp-content/uploads/2019/05/SAWC-Spring-2019.jpg "Consolidation, M&A Integrations as a Competitive Advantage, and Other Advanced Wound Care Industry Insights from 1H 2019 and SAWC Spring [Video]")
At the recent Symposium on Advanced Wound Care (SAWC Spring 2019), there were several interesting developments and companies to watch (scroll down for a video interview we did with one of them). But without a doubt, the major advanced wound care (AWC) industry theme in the first half of 2019 has been consolidation. Given the … Read More
What happened? Smith & Nephew (NYSE: SNN) will be acquiring Osiris Therapeutics (NASDAQ: OSIR) for $660M. The investment, announced today, potentially repositions Smith & Nephew within the CTP (cellular and tissue-based products) space. If the deal goes through, it will be Smith & Nephew’s most significant M&A deal within that space since the acquisition of … Read More